TABLE 5.

Simulation results comparing target attainment between intermittent bolus and continuous infusion

	Mild (initial FVIII >.05 IU/ml)			Moderate (initial FVIII .01–.05 IU/ml)			Severe (initial FVIII < .01 IU/ml)
	<.8 IU/ml N (%)	.8–1.2 IU/ml N (%)	>1.2 IU/ml N (%)	<.8 IU/ml N (%)	.8–1.2 IU/ml N (%)	>1.2 IU/ml N (%)	<.8 IU/ml N (%)	.8–1.2 IU/ml N (%)	>1.2 IU/ml N (%)
DAY 1 (Hour 0–24)
IB	113 (22.6)	174 (34.8)	213 (42.6)	159 (31.8)	172 (34.4)	169 (33.8)	173 (34.6)	176 (35.2)	151 (30.2)
CI	108 (21.6)	175 (35.0)	217 (43.4)	183 (36.6)	156 (31.2)	161 (32.2)	181 (36.2)	174 (34.8)	145 (29.0)
DAY 2 (Hour 24–48)
IB	6 (1.2)	74 (14.8)	420 (84.0)	28 (5.6)	100 (20.0)	372 (74.4)	32 (6.4)	105 (21)	363 (72.6)
CI	37 (7.4)	141 (28.2)	322 (64.4)	103 (20.6)	177 (35.4)	220 (44.0)	104 (20.8)	185 (37.0)	211 (42.2)

Abbreviations: IB, intermittent bolus; CI, continuous infusion; N, number of patients.

This table describes the proportion of 500 virtual patients that received either IB or CI FVIII dose.

The number of patients that fall within each category (i.e., subtherapeutic <.8 IU/ml, at goal .8–1.2 IU/ml, and supratherapeutic >1.2 IU/ml) was described in total numbers and percentages.